Inspire Investing LLC Makes New $1.70 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Inspire Investing LLC purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the first quarter, Holdings Channel reports. The institutional investor purchased 35,271 shares of the company’s stock, valued at approximately $1,698,000.

Several other institutional investors have also recently made changes to their positions in KNSA. Amundi purchased a new stake in Kiniksa Pharmaceuticals International in the first quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the period. Millennium Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Creative Planning purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $358,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

KNSA has been the topic of several research reports. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Wedbush upped their price objective on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $62.71.

Kiniksa Pharmaceuticals International Stock Up 2.5%

NASDAQ:KNSA opened at $63.95 on Wednesday. The stock has a market capitalization of $4.92 billion, a price-to-earnings ratio of 71.06 and a beta of 0.12. Kiniksa Pharmaceuticals International, plc has a 52 week low of $26.27 and a 52 week high of $64.81. The firm has a 50 day moving average of $52.89 and a 200 day moving average of $47.30.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.11 earnings per share. As a group, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 48,565 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the transaction, the chief executive officer directly owned 48,565 shares in the company, valued at $2,623,481.30. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.